← All trials
NCT03555188
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2018
- Primary completion
- Feb 1, 2020
- Completion date
- Feb 28, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LeedsLead sponsor
- University of LondonCollaborator
- University of BirminghamCollaborator
- University of LeedsCollaborator
- Sheffield Hallam UniversityCollaborator
- National Institute for Health Research, United KingdomCollaborator
- University of NottinghamStudy chair
- Flinders UniversityCollaborator
- University of ManchesterCollaborator
- University Hospitals of North Midlands NHS TrustCollaborator
- Barnsley Hospital NHS Foundation TrustCollaborator
- County Durham and Darlington NHS Foundation TrustCollaborator
- Lothian Health BoardCollaborator
- Barts & The London NHS TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.